Analyst Price Targets — RHHBY
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 7, 2026 6:52 am | Sarita Kapila | Morgan Stanley | $63.00 | $56.17 | StreetInsider | Morgan Stanley Upgrades Roche (RHHBY) to Overweight |
| December 10, 2025 11:17 am | — | HSBC | $57.00 | $48.66 | TheFly | Roche price target raised to $57 from $50 at HSBC |
| October 2, 2025 9:07 am | Rajesh Kumar | HSBC | $50.00 | $44.83 | TheFly | Roche upgraded to Buy from Hold at HSBC (yesterday) |
| June 27, 2022 8:11 am | — | Cowen & Co. | $48.00 | $41.64 | Benzinga | Cowen & Co. Maintains Outperform on Roche Holding, Lowers Price Target to $48 |
Latest News for RHHBY
The Swiss drugmaker will assume responsibility for outside China, Hong Kong, Macau and Taiwan after the completion of early-stage clinical trials.
Roche to unveil lung, breast cancer data at ESMO 2026
RHHBY wins FDA approval for Enspryng in thyroid eye disease, offering the first and only at-home subcutaneous treatment option for patients.
AZN, RHHBY, PBYI and OLMA offer exposure to breast cancer drug sales growth, expanded treatment approvals and clinical milestones that could shape prospects.
RHHBY expands its obesity pipeline with a novel RNAi candidate targeting ALK7, while advancing enicepatide and other late-stage drugs to strengthen its metabolic disease ambitions.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for RHHBY.
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.